StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.84−0.01 (-0.87%)

Close on Nov 18, 2026Market cap $65.27MP/E –Yield –

Cardiff Oncology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Cardiff Oncology's ebitda for the twelve months ending Jun 30, 2026 was -$41.92M. For fiscal 2025 it was -$48.60M. The highest annual figure on record is -$2.97M in fiscal 2011.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.60M–
FY2024Dec 31, 2024-$48.25M–
FY2023Dec 31, 2023-$45.01M–
FY2022Dec 31, 2022-$39.67M–
FY2021Dec 31, 2021-$28.40M–
FY2020Dec 31, 2020-$18.62M–
FY2019Dec 31, 2019-$16.18M–
FY2018Dec 31, 2018-$16.19M–
FY2017Dec 31, 2017-$24.35M–
FY2016Dec 31, 2016-$39.08M–
FY2015Dec 31, 2015-$24.89M–
FY2014Dec 31, 2014-$14.71M–
FY2013Dec 31, 2013-$10.56M–
FY2012Dec 31, 2012-$4.81M–
FY2011Dec 31, 2011-$2.97M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.53M–
Q1 FY2026Mar 31, 2026-$12.76M–
Q4 FY2025Dec 31, 2025-$7.74M–
Q3 FY2025Sep 30, 2025-$11.89M–
Q2 FY2025Jun 30, 2025-$14.68M–
Q1 FY2025Mar 31, 2025-$14.29M–
Q4 FY2024Dec 31, 2024-$12.48M–
Q3 FY2024Sep 30, 2024-$12.50M–
Q2 FY2024Jun 30, 2024-$12.44M–
Q1 FY2024Mar 31, 2024-$10.83M–
Q4 FY2023Dec 31, 2023-$10.23M–
Q3 FY2023Sep 30, 2023-$10.71M–
Q2 FY2023Jun 30, 2023-$12.11M–
Q1 FY2023Mar 31, 2023-$11.96M–
Q4 FY2022Dec 31, 2022-$9.31M–
Q3 FY2022Sep 30, 2022-$8.91M–
Q2 FY2022Jun 30, 2022-$10.41M–
Q1 FY2022Mar 31, 2022-$11.04M–
Q4 FY2021Dec 31, 2021-$9.41M–
Q3 FY2021Sep 30, 2021-$6.89M–
Q2 FY2021Jun 30, 2021-$6.78M–
Q1 FY2021Mar 31, 2021-$5.32M–
Q4 FY2020Dec 31, 2020-$6.38M–
Q3 FY2020Sep 30, 2020-$4.25M–
Q2 FY2020Jun 30, 2020-$3.99M–
Q1 FY2020Mar 31, 2020-$4.01M–
Q4 FY2019Dec 31, 2019-$4.17M–
Q3 FY2019Sep 30, 2019-$4.08M–
Q2 FY2019Jun 30, 2019-$4.10M–
Q1 FY2019Mar 31, 2019-$3.83M–
Q4 FY2018Dec 31, 2018-$3.95M–
Q3 FY2018Sep 30, 2018-$3.64M–
Q2 FY2018Jun 30, 2018-$4.21M–
Q1 FY2018Mar 31, 2018-$4.40M–
Q4 FY2017Dec 31, 2017-$3.49M–
Q3 FY2017Sep 30, 2017-$5.49M–
Q2 FY2017Jun 30, 2017-$5.57M–
Q1 FY2017Mar 31, 2017-$9.79M–
Q4 FY2016Dec 31, 2016-$9.41M–
Q3 FY2016Sep 30, 2016-$9.72M–

More Cardiff Oncology figures

See a number that looks wrong?